Lincomycin Injection 300mgml

Χώρα: Μαλαισία

Γλώσσα: Αγγλικά

Πηγή: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Δραστική ουσία:

LINCOMYCIN HCL

Διαθέσιμο από:

Y.S.P. INDUSTRIES (M) SDN. BHD.

INN (Διεθνής Όνομα):

LINCOMYCIN HCL

Μονάδες σε πακέτο:

100.00 mcg/mL

Κατασκευάζεται από:

YUNG SHIN PHARMACEUTICAL IND. CO., LTD.

Αρχείο Π.Χ.Π.

LINCOMYCIN INJECTION
300MG/ML
INGREDIENT(S):
Each ml contains:
Lincomycin HCl.………………........................300mg/ml
(potency)
Preservative(s):
Each ml contains:
Methyl paraben …………………………………………. 1.1mg
Propyl paraben ………………………………………….
0.122mg
PHARMACOLOGY (SUMMARY OF PHARMACODYNAMICS AND
PHARMACOKINETICS):
Lincomycin may be bacteriostatic or bactericidal in action, depending
on the
concentrations
of
the
drug
attained
at
the
site
of
infection
and
the
susceptibility of the infecting organism. Lincomycin appears to
inhibit protein
synthesis in susceptible organisms by binding to the 50S ribosomal
subunit,
thereby inhibiting peptide bond formation.
Following oral administration, lincomycin is rapidly absorbed from the
gut,
but only about 30~40% of the total dose is absorbed. Food both
decreases
the extent and the rate of absorption. Peak serum levels are attained
about
2~4 hours after oral dosing. IM administration gives peak levels about
double those reached after oral dosing, and peak at about 30 minutes
post
injection.
Lincomycin is distributed into most tissues. Therapeutic levels are
achieved
in bone, synovial fluid, bile, pleural fluid, peritoneal fluid, skin,
and heart
muscle. CNS levels may reach 40% of those in the serum if meninges are
inflamed. Lincomycin is bound from 57~72% to plasma proteins,
depending
on the drug’s concentration. The drug crosses the placenta and also
can be
distributed into milk at concentrations equal to those found in the
plasma.
Lincomycin
is
partially
metabolised
in
the
liver.
Unchanged
drug
and
metabolites are excreted in the urine, feces and bile. The elimination
half-life
of
Lincomycin
is
reportedly
3~4
hours
in
small
animals,
and
can
be
prolonged in patients with renal or hepatic dysfunction.
INDICATION(S):
1) For the treatment of infectious forms of arthritis caused by
Staphylococci,
Streptococci, Erysipelothrix and _Mycoplasma spp._
2) For the treatment of mycoplasma pneumonia.
TARGET SPECIES
Swine.